Literature DB >> 27743339

Mutant KRAS Status Is Associated with Increased KRAS Copy Number Imbalance: a Potential Mechanism of Molecular Heterogeneity.

Ottó Dócs1, Katalin Hegyi1, Attila Mokánszky1, Anikó Mónusné1, Lívia Beke1, Csilla András2, Judit Bedekovics1, Gábor Méhes3.   

Abstract

Mutation rates determined by allele-specific PCR can be highly different in KRAS exon 2 mutant colorectal carcinoma (CRC) samples suggesting intratumoural heterogeneity. To address the effect of KRAS gene copy number on the relative mutant allele frequency the KRAS locus was individually quantified following FISH analysis in 36 cases. We observed, that mutant KRAS status was associated with an elevated KRAS locus number (2.36 ± 0.42 vs 2.63 ± 0.75; p = 0.037) reflecting an increased aneuploidy status but no true amplification of the locus. In parallel, KRAS locus copy numbers showed significant intercellular variability (1-16 copies/cell nucleus) within individual tumours also indicating to a dynamic intratumoural oscillation of the mutant allele copy number. In conclusion, aneusomy is a common feature of KRAS mutant CRC and KRAS copy number variations may have an impact on the relative mutant allele frequency detected by allele specific PCR/sequencing), potentially leading to subclonal diversity and influencing tumour behaviour.

Entities:  

Keywords:  Amplification; CEP12; Colorectal cancer; Heterogeneity; KRAS

Mesh:

Substances:

Year:  2016        PMID: 27743339     DOI: 10.1007/s12253-016-0126-x

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  17 in total

Review 1.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

Authors:  J H J M van Krieken; A Jung; T Kirchner; F Carneiro; R Seruca; F T Bosman; P Quirke; J F Fléjou; T Plato Hansen; G de Hertogh; P Jares; C Langner; G Hoefler; M Ligtenberg; D Tiniakos; S Tejpar; G Bevilacqua; A Ensari
Journal:  Virchows Arch       Date:  2008-09-18       Impact factor: 4.064

2.  Gene expression analysis identifies global gene dosage sensitivity in cancer.

Authors:  Rudolf S N Fehrmann; Juha M Karjalainen; Małgorzata Krajewska; Harm-Jan Westra; David Maloney; Anton Simeonov; Tune H Pers; Joel N Hirschhorn; Ritsert C Jansen; Erik A Schultes; Herman H H B M van Haagen; Elisabeth G E de Vries; Gerard J te Meerman; Cisca Wijmenga; Marcel A T M van Vugt; Lude Franke
Journal:  Nat Genet       Date:  2015-01-12       Impact factor: 38.330

3.  Single base pair mutation analysis by PNA directed PCR clamping.

Authors:  H Orum; P E Nielsen; M Egholm; R H Berg; O Buchardt; C Stanley
Journal:  Nucleic Acids Res       Date:  1993-11-25       Impact factor: 16.971

4.  Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Authors:  Federico Cappuzzo; Fred R Hirsch; Elisa Rossi; Stefania Bartolini; Giovanni L Ceresoli; Lynne Bemis; Jerry Haney; Samir Witta; Kathleen Danenberg; Irene Domenichini; Vienna Ludovini; Elisabetta Magrini; Vanesa Gregorc; Claudio Doglioni; Angelo Sidoni; Maurizio Tonato; Wilbur A Franklin; Lucio Crino; Paul A Bunn; Marileila Varella-Garcia
Journal:  J Natl Cancer Inst       Date:  2005-05-04       Impact factor: 13.506

5.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Delphine Le Corre; Valérie Boige; Bruno Landi; Jean-François Emile; Jean-François Côté; Gorana Tomasic; Christophe Penna; Michel Ducreux; Philippe Rougier; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

6.  KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy.

Authors:  Emanuele Valtorta; Sandra Misale; Andrea Sartore-Bianchi; Iris D Nagtegaal; François Paraf; Calogero Lauricella; Valentina Dimartino; Sebastijan Hobor; Bart Jacobs; Cristiana Ercolani; Simona Lamba; Elisa Scala; Silvio Veronese; Pierre Laurent-Puig; Salvatore Siena; Sabine Tejpar; Marcella Mottolese; Cornelis J A Punt; Marcello Gambacorta; Alberto Bardelli; Federica Di Nicolantonio
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

7.  Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.

Authors:  R Seth; S Crook; S Ibrahem; W Fadhil; D Jackson; M Ilyas
Journal:  Gut       Date:  2009-05-26       Impact factor: 23.059

8.  Changes of KRAS Exon 2 Codon 12/13 Mutation Status in Recurrent Colorectal Cancer.

Authors:  Ottó Dócs; Ferenc Fazakas; Nóra Lugosiné Horváth; László Tóth; Csilla András; Zsolt Horváth; Gábor Méhes
Journal:  Pathol Oncol Res       Date:  2014-09-24       Impact factor: 3.201

9.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

10.  The epigenetic origin of aneuploidy.

Authors:  Luis A Herrera; Diddier Prada; Marco A Andonegui; Alfonso Dueñas-González
Journal:  Curr Genomics       Date:  2008-03       Impact factor: 2.236

View more
  2 in total

1.  KRAS-retroviral fusion transcripts and gene amplification in arsenic-transformed, human prostate CAsE-PE cancer cells.

Authors:  B Alex Merrick; Dhiral P Phadke; Meredith A Bostrom; Ruchir R Shah; Garron M Wright; Xinguo Wang; Oksana Gordon; Katherine E Pelch; Scott S Auerbach; Richard S Paules; Michael J DeVito; Michael P Waalkes; Erik J Tokar
Journal:  Toxicol Appl Pharmacol       Date:  2020-04-25       Impact factor: 4.219

2.  Arsenite malignantly transforms human prostate epithelial cells in vitro by gene amplification of mutated KRAS.

Authors:  B Alex Merrick; Dhiral P Phadke; Meredith A Bostrom; Ruchir R Shah; Garron M Wright; Xinguo Wang; Oksana Gordon; Katherine E Pelch; Scott S Auerbach; Richard S Paules; Michael J DeVito; Michael P Waalkes; Erik J Tokar
Journal:  PLoS One       Date:  2019-04-22       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.